Editor's choice
European Oncology & Haematology, 2016;12(1):51–4 DOI: http://doi.org/10.17925/EOH.2016.12.01.51
Latest Articles
European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51
European Oncology & Haematology, 2016;12(1):51–4 DOI: http://doi.org/10.17925/EOH.2016.12.01.51
Oncology & Hematology Review, 2016;12(1):41–6 DOI: http://doi.org/10.17925/OHR.2016.12.01.41
Oncology & Hematology Review, 2015;11(2):141–2 DOI: http://doi.org/10.17925/OHR.2015.11.02.141
Oncology & Hematology Review, 2015;11(2):137–8 DOI: http://doi.org/10.17925/OHR.2015.11.02.137
Oncology & Hematology Review, 2012;8(1):43–7 DOI: http://doi.org/10.17925/OHR.2012.08.1.43
European Oncology & Haematology, 2012;8(3):162-6 DOI: http://doi.org/10.17925/EOH.2012.08.3.162
Latest Videos
Video List based on Category on Node Page
Latest Videos
Jeff Evans discusses the key findings from the phase III REFLECT study, and how these results might impact the future management of liver cancer patients.
Speaker disclosures: Consultancy for Eisai for Advisory Boards. Support for clinical trials (all payments to university).
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017
Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%.
After local chemotherapy of the liver, the catheter filters out excess drug that is prevented from travelling to the rest of the body. This minimizes the potential for toxic side effects and may allow the use of higher local doses that increase treatment efficacy.